Preparation and identification of novel DPP-IV inhibitory peptides from Musculus senhousei: Peptidomic analysis, molecular simulation, and validation

Bioactive peptides have been considered effective alternatives for the treatment of type 2 diabetes targeting the dipeptidyl peptidase-IV (DPP-IV). In this study, novel DPP-IV inhibitory peptides were prepared and identified from Musculus senhousei through two-stage chromatographic purification, pep...

Descripción completa

Detalles Bibliográficos
Autores: Zhou, Liuyang, Xiao, Chuqiao, Gao, Jie, Zhao, Mouming, Li, Xiang Guang, Mora, Leticia, Toldrá Vilardell, Fidel
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/382117
Acceso en línea:http://hdl.handle.net/10261/382117
https://api.elsevier.com/content/abstract/scopus_id/85187363042
Access Level:acceso abierto
Palabra clave:Asian date mussel
Bioactive peptides
LC-MS/MS
Peptide-enzyme interaction
bioactive compounds
peptides
Descripción
Sumario:Bioactive peptides have been considered effective alternatives for the treatment of type 2 diabetes targeting the dipeptidyl peptidase-IV (DPP-IV). In this study, novel DPP-IV inhibitory peptides were prepared and identified from Musculus senhousei through two-stage chromatographic purification, peptidomic analysis, in silico screening, and validation. Furthermore, molecular simulation was employed to analyze the interaction from a molecular perspective. Results showed that Musculus senhousei hydrolysate produced by 8 h Neutrase hydrolysis exhibited the significant DPP-IV inhibitory activity. Purification and identification led to the discovery of 387 peptide sequences. A total of 11 novel peptides with potential DPP-IV inhibitory activity were screened in silico. Further synthesis and validation of peptide activity showed that LTWR and DPF significantly inhibit DPP-IV in a competitive inhibitory manner, with IC50 values of 1788.67 ± 28.13 and 1399.73 ± 27.15 μM, respectively. Results from molecular docking and dynamic simulations indicated that peptides LTWR and DPF could tightly bind to the catalytic site of DPP-IV through hydrogen-bond and hydrophobic interaction. These findings suggested that Musculus senhousei could serve as a natural source of bioactive peptides for potential treatment of type 2 diabetes.